Credit: Daniel Hanoch
In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem s Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19.
The study was presented at the recent SPARK Conference on Generic Drug Repurposing for COVID-19 by Professor Yaakov Nahmias, Director of the Center for Bioengineering at Hebrew University. Nahmias applied a well-established existing drug to address the buildup of fats in human lung cells caused by the SARS-CoV-2 virus. Initial lab-based results and new data from 1,500 Israel-based Corona patients have been extremely promising and clinical studies are scheduled to begin this week at Barzilai Hospital in Ashkelon, Israel, joining other clinical centers across the United States, South America and Europe.
Promising clinical data for fenofibrate s ability to prevent lung damage in COVID-19 patients
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Initial Hebrew U Clinical Data Support Fenofibrate s Effectiveness in Preventing Lung Damage in Corona Patients | The Jewish Press - JewishPress com | David Israel | 6 Tevet 5781 – December 21, 2020
jewishpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jewishpress.com Daily Mail and Mail on Sunday newspapers.